CHMP Backs Baxfendy, Revives Aumseqa, Flags Mounjaro-Contraceptive Risk
CHMP positive opinions cover AstraZeneca's Baxfendy, Hansoh's Aumseqa and Innovent's Zybrivo, plus a precaution on Mounjaro and oral contraceptives heading to the EC.
TAG T-7849 · 664 words on the filing

Summary of findings
- CHMP issued positive opinions for three new drugs, two biosimilars and two generics, plus 11 label extensions at its November meeting.
- Aumseqa could regain EU marketing authorization after the European Commission revoked it in September over AstraZeneca data-use claims.
- Baxfendy, acquired via the $1.3 billion CinCor buyout in 2023, anchors AstraZeneca's $80 billion 2030 sales target.
- CHMP advised women on Mounjaro to add barrier contraception for 4 weeks after initiation and after each dose increase.
- Zybrivo's EU application now rests with the EC after the FDA rejected it in 2022 over China-only data.
Europe's drug regulators handed down a full slate of decisions at their November meeting: positive opinions for three new drugs, two biosimilars and two generics, plus recommended label extensions for 11 approved medicines and a formal warning to physicians about a potential interaction between GLP-1 therapies and oral contraceptives.
All recommendations now go to the European Commission for final sign-off. For market-access teams, the single most consequential item is the revival of a lung cancer drug whose EU license was pulled barely two months ago.
What does the Aumseqa decision change?
The CHMP issued a positive opinion for Aumseqa, the non-small-cell lung cancer treatment partnered between Hansoh and SFL Pharma, opening a path for the European Commission to reinstate a commercial license the EC revoked in September.
The drug's approval history is tangled. After a four-year process, the CHMP first recommended it in November 2025 and the EC approved it in February. In September, the EC withdrew the authorization after determining that the original 2022 application violated data protection rules by referencing AstraZeneca's data for the competitor product Tagrisso. That revocation followed a lawsuit AstraZeneca filed against the agency in the EU's General Court.
Aumseqa has generated no sales outside China. It nonetheless poses a credible challenge to Tagrisso, the world's best-selling EGFR inhibitor, which booked nearly $3.8 billion in sales in the first half of 2026.
Where does Baxfendy fit in AstraZeneca's plan?
AstraZeneca secured a positive recommendation for Baxfendy, its first-in-class blood pressure medicine, as a treatment for insufficiently controlled hypertension. The company acquired the aldosterone synthase inhibitor through its $1.3 billion buyout of CinCor Pharma in 2023 and won FDA approval earlier this year.
The drug carries strategic weight. AstraZeneca has built Baxfendy into its plan to reach $80 billion in total sales by 2030, and the company has signaled peak sales could exceed $5 billion.
Can Zybrivo finally reach a Western market?
The third new-drug positive opinion went to Zybrivo for non-squamous non-small cell lung cancer. Innovent Biologics and Eli Lilly co-developed the drug, which China approved in 2018, but its global path has been difficult.
The FDA rejected Zybrivo's application in 2022, citing China-only data and an outdated control group. Lilly then returned non-China rights to Innovent, whose subsidiary Fortvita Biologics now carries the EU application forward. EC approval is pending. The drug enters a market dominated by Merck's Keytruda, and its commercial fight remains steep.
What did Merck and the rest of the label-expansion list gain?
Merck picked up three expansion recommendations:
- Enflonsia, a monoclonal antibody, extended to children up to 24 months old at increased risk of respiratory syncytial virus.
- Welireg, the first-in-class oral HIF-2α inhibitor, recommended with lenvatinib (Lenvima) in advanced clear cell renal cell carcinoma that progressed after prior therapy including a PD-(L)1 inhibitor.
- Steglatro, the type 2 diabetes medicine, recommended alongside diet and exercise in children aged 10 and up whose diabetes is not adequately controlled.
Medicines from Gilead, Pfizer, ViiV and Roche also secured expansion recommendations.
What does the CHMP's Mounjaro warning require?
The committee voted to adopt an official communication to providers about Mounjaro's potential effect on the reliability of oral contraceptives. Contraception is already recommended for women on Mounjaro who can become pregnant, but little is known about interactions with oral contraceptives specifically.
The guidance advises women taking Mounjaro and an oral contraceptive to switch to a non-oral contraceptive or add a barrier method for 4 weeks after starting Mounjaro and for 4 weeks after every dose increase.
A Lilly spokesperson said the company "is updating the European product information for Mounjaro® (tirzepatide) with revised contraception guidance for women of childbearing potential," and characterized the change as a "precautionary update."
The communication, together with the approval and expansion recommendations, now awaits the European Commission's final decision.
via Fierce Pharma (Google News) (Source)
More from Olivia Hart
Show full bio
Senior reporter covering money, funding and market shifts around global pharmaceutical industry at PharmInsider.
22 articles
Linked filings
- P-6323
- C-7166
- K-1065
- T-7165
- C-4460